NCT04160494 - D2C7-IT With Atezolizumab for Recurrent Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

June 28, 2024

Study Completion Date

December 31, 2027

Conditions

Malignant Glioma

Interventions

DRUG

D2C7-IT (6920 ng/mL via convection-enhanced delivery)

dual-specific mAB

DRUG

Atezolizumab (1200 mg every three weeks)

programmed cell death ligand 1 (PD-L1) blocking antibody

DRUG

D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)

dual-specific mAB

Trial Locations (1)

Duke University Medical Center, Durham